瑞博生物-B(06938)就若干siRNA资产与Madrigal订立独家全球授权协议

智通财经02-11

智通财经APP讯，瑞博生物-B(06938)发布公告，于2026年2月11日(交易时段后)，本公司及其附属公司Ribocure Pharmaceuticals AB与Madrigal Pharmaceuticals, Inc. (纳斯达克股份代号：MDGL)(Madrigal)就开发六款针对代谢功能障碍相关脂肪性肝炎(MASH)的临床前小干扰核酸(siRNA)疗法订立独家全球授权协议(该协议)。...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2610933555?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-02-11 18:03","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2610933555","market":"fut","top_or_hot":-1,"title":"瑞博生物-B(06938)就若干siRNA资产与Madrigal订立独家全球授权协议","media":"智通财经","content":"<div>\n<p>智通财经APP讯，瑞博生物-B(06938)发布公告，于2026年2月11日(交易时段后)，本公司及其附属公司Ribocure Pharmaceuticals AB与Madrigal Pharmaceuticals, Inc. (纳斯达克股份代号：MDGL)(Madrigal)就开发六款针对代谢功能障碍相关脂肪性肝炎(MASH)的临床前小干扰核酸(siRNA)疗法订立独家全球授权协议(该协议)。...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1404239.html\">网页链接</a>\n\n</div>\n","source":"stock_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>瑞博生物-B(06938)就若干siRNA资产与Madrigal订立独家全球授权协议</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n瑞博生物-B(06938)就若干siRNA资产与Madrigal订立独家全球授权协议\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-02-11 18:03 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/1404239.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP讯，瑞博生物-B(06938)发布公告，于2026年2月11日(交易时段后)，本公司及其附属公司Ribocure Pharmaceuticals AB与Madrigal Pharmaceuticals, Inc. (纳斯达克股份代号：MDGL)(Madrigal)就开发六款针对代谢功能障碍相关脂肪性肝炎(MASH)的临床前小干扰核酸(siRNA)疗法订立独家全球授权协议(该协议)。...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1404239.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"06938","symbol_name":"瑞博生物-B","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1404239.html","article_id":"2610933555","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2610933555","pubTimestamp":1770804224,"columns":[],"sourceInfo":{"source_id":"stock_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"智通财经APP讯，瑞博生物-B 发布公告，于2026年2月11日，本公司及其附属公司Ribocure Pharmaceuticals AB与Madrigal Pharmaceuticals, Inc. 就开发六款针对代谢功能障碍相关脂肪性肝炎的临床前小干扰核酸疗法订立独家全球授权协议(该协议)。根据该协议，本公司已授予Madrigal独家全球授权，以运用本公司的 RiboGalSTARTM及siRNA化学修饰平台，开发、生产及商业化若干临床前单靶点及双靶点siRNA资产。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"06938":"瑞博生物-B","BK1161":"生物科技"},"translate_title":"Ruibo Bio-B (06938) entered into an exclusive global licensing agreement with Madrigal for certain siRNA assets","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"06938":1.5},"content_text":"智通财经APP讯，瑞博生物-B(06938)发布公告，于2026年2月11日(交易时段后)，本公司及其附属公司Ribocure Pharmaceuticals AB与Madrigal Pharmaceuticals, Inc. (纳斯达克股份代号：MDGL)(Madrigal)就开发六款针对代谢功能障碍相关脂肪性肝炎(MASH)的临床前小干扰核酸(siRNA)疗法订立独家全球授权协议(该协议)。根据该协议，本公司已授予Madrigal独家全球授权，以运用本公司的 RiboGalSTARTM及siRNA化学修饰平台，开发、生产及商业化若干临床前单靶点及双靶点siRNA资产。本集团将收取6000万美元的首付款，倘达成若干开发、监管及商业化里程碑，累计可获得44亿美元付款，外加净销售额的潜在特许权使用费。于本公告日期，该协议所规定的里程碑付款须待达成若干条件后方可作实，故此本公司最终可获得的里程碑付款金额仍存在不确定性。此合作将利用本公司经验证的肝靶向RiboGalSTARTM平台，开发MASH的新疗法，标志本公司于成为全球领先的创新siRNA企业的道路上的重大里程碑，同时加快本公司全球开发和商业化策略，为MASH患者的未被满足医疗需求推出更具靶向性、更有效的疗法。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.4","shortVersion":"4.42.4","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2610933555","isCrawlerRequest":true}